Aclaris Therapeutics to Present Scientific Posters at the 77th Annual Meeting of the American Academy of Dermatology
Phase 2 Clinical Study Results in Treatment of Common Warts Selected for Oral Presentations
WAYNE, Pa., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today announced that posters summarizing the clinical results of a Phase 2 clinical trial of its investigational medicine, A-101 45% topical solution for the treatment of common warts, have been selected for oral presentation during the American Academy of Dermatology (AAD) Annual Meeting to be held March 1 - 5, 2019 in Washington, D.C.
The details of the e-posters with oral presentations are as follows:
- Long-Term Efficacy and Safety of Hydrogen Peroxide Topical Solution, 45% (w/w) in Patients with Common Warts: Posttreatment Results from the Phase 2 WART-203 Trial
- Poster 10224
- Date and time of oral presentation: Saturday, March 2, 10:25 a.m. to 10:30 a.m.
- Location of oral presentation: Hall H, ePoster Presentation Center 2
- Efficacy and Safety of Hydrogen Peroxide Topical Solution, 45% (w/w) for Treatment of Common Warts: 8-Week Results from the Phase 2 WART-203 Trial
- Poster 10150
- Date and time of oral presentation: Sunday, March 3, 10:20 a.m. to 10:25 a.m.
- Location of oral presentation: Hall H, ePoster Presentation Center 1
In addition, the following original abstracts were accepted for e-poster presentation during the meeting:
- Poster 10235 - Rater Reliability Testing of the Physician Wart Assessment for Common Warts: A Noninterventional, Observational Study
- Poster 10497 - Effectiveness of Hydrogen Peroxide Topical Solution 40% and 45% (w/w) in Patients with Seborrheic Keratoses on the Trunk, Extremities, and Face: Results of a Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study
- Poster 10513 - Safety of Hydrogen Peroxide Topical Solution 40% and 45% (w/w) in Patients with Seborrheic Keratoses on the Trunk, Extremities, and Face: Results of a Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study
- Poster 10527 - Onset of Treatment Effectiveness with Hydrogen Peroxide Topical Solution 40% and 45% (w/w) in Patients with Seborrheic Keratoses on the Trunk, Extremities and Face: Results of a Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study
About A-101 45% Topical Solution
A-101 45% topical solution, an investigational medicine for the treatment of common warts, is a proprietary, stabilized, high concentration hydrogen peroxide topical solution, 45% (w/w), also referred to as HP45. It is being developed as a topical, non-invasive treatment for self-administration or administration by a caregiver. If approved, A-101 45% topical solution would be the first prescription medicine approved by the FDA for the treatment of common warts.
About Common Warts
Common warts, also called verruca vulgaris, are skin growths caused by a virus infecting the top layer of the skin. They affect an estimated 22 million Americans each year with a higher incidence in children than adults. Common warts are often skin-colored and feel rough but can be darker and smooth. Symptoms include pain, bleeding, itching, and burning. Common warts are contagious and may interfere with social activities, cause embarrassment, and carry a social stigma. Each year, over 2 million people in the U.S. are diagnosed with common warts during a visit to a health care professional.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology. Aclaris’ focus on market segments with no FDA-approved medications or where treatment gaps exist has resulted in the first FDA-approved treatment for raised seborrheic keratoses and several clinical programs to develop medications for the potential treatment of common warts, alopecia areata, and vitiligo. For additional information, please visit and follow Aclaris on LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan," "potential," "will," and similar expressions, and are based on Aclaris' current beliefs and expectations. These forward-looking statements include expectations regarding Aclaris’ clinical development of its investigational medicine, A-101 45% topical solution. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris' reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of Aclaris' Annual Report on Form 10-K filed for the year ended December 31, 2017, Aclaris’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the "SEC filings" section of the Investors page of Aclaris' website at . Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Aclaris Therapeutics Contacts
Investor Contact
Michael Tung, M.D.
Senior Vice President
Corporate Strategy/Investor Relations
484-329-2140
Media Contact
Sheila Kennedy
Vice President, Corporate Communications
484-321-5559
